# A Study in Moderate to Severe Rheumatoid Arthritis Participants

> **NCT01721057** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 684 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Baricitinib
- **DRUG:** cDMARD

## Key facts

- **NCT ID:** NCT01721057
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721057, "A Study in Moderate to Severe Rheumatoid Arthritis Participants". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT01721057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*